Highest-materiality recent filing
Alkermes announces orphan drug designations for alixorexton in US for IH and EU for narcolepsy
FDA grants orphan drug designation to alixorexton for idiopathic hypersomnia.
LUMRYZ meets all primary, key secondary endpoints in Phase 3 idiopathic hypersomnia study
Primary endpoint ESS showed statistically significant improvement vs placebo (p<0.0001).
Alkermes Q1 revenue $392.9M; GAAP net loss $66.5M after Avadel acquisition costs
Q1 total revenues $392.9M, up 28% YoY; GAAP net loss $66.5M vs. income of $22.5M in Q1 2025.
Alkermes completes Avadel acquisition; pro forma net income $13.8M, EPS $0.08
Acquisition closed Feb 12, 2026; total cash consideration $21.00 per Avadel share plus CVR up to $1.50 per share.
Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal
Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.
Alkermes CEO Richard Pops to retire July 31, 2026; COO Blair Jackson named successor
Richard Pops retires as CEO effective July 31, 2026, after 35-year tenure; will remain Chairman and Senior Advisor through Dec 31, 2026.
Alkermes closes Avadel acquisition for $21/share cash + CVR; funded with $1.525B term loans
Consideration: $21.00/sh cash plus one non-transferable CVR (potential $1.50/sh) per Avadel share.
Alkermes gets FDA Breakthrough Therapy designation for alixorexton in narcolepsy type 1
FDA granted Breakthrough Therapy designation based on phase 1/2 data including Vibrance-1 study (n=92).
Alkermes raises Avadel offer to $21.00 cash plus $1.50 CVR per share
Cash consideration raised to $21.00/share from $18.50; CVR of $1.50/share unchanged.
Alkermes' alixorexton meets dual primary endpoints in Phase 2 narcolepsy type 2 study
Alixorexton (10, 14, 18 mg) showed statistically significant improvements vs placebo on MWT and ESS at week 8.
Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance
Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.
Alkermes to acquire Avadel for $18.50/share plus up to $1.50 CVR; $1.23B bridge financing arranged
Cash consideration of $18.50 per Avadel share; CVR for additional $1.50 upon FDA approval of LUMRYZ and legal settlement.
Alkermes sues Teva, Apotex, MSN over LYBALVI patents; enters VIVITROL AG deal with Amneal
Filed patent lawsuits against Teva (8/15), Apotex (8/27), MSN (9/5) over generic LYBALVI; 30-month FDA stays triggered.
Alkermes' alixorexton meets primary endpoint in phase 2 NT1 study; all doses improve wakefulness
Primary endpoint: MWT mean sleep latency improved by 22.2-26.0 min vs placebo -0.6 min (p<0.01 all doses).
Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY
Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.
Alkermes reports positive phase 2 results for alixorexton in narcolepsy type 1; primary endpoint met
Alixorexton met primary endpoint: statistically significant and dose-dependent improvements in wakefulness (MWT) vs placebo (p<0.0001 at all doses).
Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance
Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).
Alkermes CFO Iain M. Brown passes away; interim leadership continues
CFO Iain M. Brown died on April 14, 2025, after a battle with cancer; on medical leave since Feb. 2024.
Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B
FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.
Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56
Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).
Alkermes Q2 2024 GAAP EPS $0.55; proprietary sales up 16% YoY; reiterates guidance
Total revenues $399.1M, GAAP net income from continuing ops $94.7M; non-GAAP net income $123.4M.
Alkermes Q1 2024 revenue $350.4M, GAAP net income $38.9M, LYBALVI sales up 50% YoY
Total revenues of $350.4M vs $287.6M in Q1 2023; GAAP net income from continuing ops $38.9M ($0.23 EPS) vs loss of $12.1M.
ALKS 2680 shows statistically significant wakefulness improvement in NT2 and IH phase 1b
ALKS 2680 improved mean sleep latency vs placebo at all doses in NT2 (5mg: +12 min, p<0.05; 12mg: +19 min, p<0.001; 25mg: +21 min, p<0.001).
Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M
GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.
Alkermes sells Athlone facility to Novo Nordisk for $92.5M; 400 employees to transfer
Asset sale of Athlone development and manufacturing facility for $92.5M cash; expected to close mid-2024.
Alkermes completes spin-off of oncology business into Mural; raises 2023 guidance
On Nov 15, 2023, distributed 1 Mural share for every 10 Alkermes shares; MURA begins trading Nov 16.
Alkermes sets Nov 6 record date, Nov 15 distribution for Mural Oncology spin-off (1:10 ratio)
Form 10 declared effective by SEC for Mural Oncology spin-off.
Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.
ALKS 2680 demonstrated dose-dependent improvement in sleep latency: +18, +30, +37 minutes vs placebo (-1 min) at 1, 3, 8 mg (p<0.01 to p<0.001).
Alkermes settles VIVITROL patent litigation with Teva; generic entry January 2027
Teva granted license to market generic VIVITROL in U.S. starting Jan 15, 2027, or earlier under certain circumstances.
Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win
Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.
Alkermes wins arbitration vs Janssen, raises 2023 outlook by ~$425M
Final arbitration award confirms Janssen must pay royalties on INVEGA and CABENUVA products; back royalties of ~$194M (incl. interest) received.
Effective March 5, 2024, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to eleven (11) directors and elected Nancy S. Lurker to the Board, with an initial term expiring at the Company’s 2024 annual general meeting of shareholders (the “2024 Annual Meeting”).
and Samuel J. Parisi, Vice President, Finance of Alkermes, Inc., as the Company's interim principal accounting officer
designated Blair C. Jackson, Executive Vice President, Chief Operating Officer of Alkermes, Inc., a wholly-owned subsidiary of the Company, as the Company's interim principal financial officer
appointed Frank Anders Wilson as the Lead Independent Director of the Board, in each case effective as of December 8, 2023.
On December 4, 2023, following ten years of service, Nancy J. Wysenski notified Alkermes plc (the “Company”) of her decision to retire, for personal reasons, from the Company’s board of directors (the “Board”) and from any Board leadership positions and committees on which she serves, in each case effective as of December 8, 2023.
David W. Anstice AO and Wendy L. Dixon, Ph.D. notified Alkermes plc (the “Company”) of their decision to retire from the Company’s board of directors (the “Board”) and from any committees of the Board on which they serve
the Board elected Dr. Christopher I. Wright to the Board, effective immediately
David W. Anstice AO and Wendy L. Dixon, Ph.D. notified Alkermes plc (the “Company”) of their decision to retire from the Company’s board of directors (the “Board”) and from any committees of the Board on which they serve
On November 18, 2021, the Board of Directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to twelve (12) directors and elected Dr. Cato T. Laurencin to the Board, effective immediately, as a Class II member with a term expiring at the Company’s 2022 annual general meeting of shareholders.
Max materiality 0.90 · Median 0.65 · Most common event other_material